Jiaqiang Ren

First Affiliated Hospital of Xi'an Jiaotong University

Immunology and MicrobiologyMedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies”.

Group O plasma as a media supplement for CAR‐T cells and other adoptive T‐cell therapies

Transfusion(2020)10.1111/trf.15745

N/A

0DataRank · unranked

0 citations

Vicki Fellowes, Ping Jin, Hui Liu, Steven L. Highfill, Jiaqiang Ren +4 more

The Potential Use of THP-1, a Monocytic Leukemia Cell Line, to Predict Immune-Suppressive Potency of Human Bone-Marrow Stromal Cells (BMSCs) In Vitro: A Pilot Study

International Journal of Molecular Sciences(2023)10.3390/ijms241713258

N/A

0DataRank · unranked

7 citations

Gergely Szombath, Lynn Vitale‐Cross, David F. Stroncek, Pamela Gehron Robey, Anna Hajdara +6 more

Expanding the reach of commercial cell therapies requires changes at medical centers

Journal of Translational Medicine(2024)10.1186/s12967-024-04966-6

N/A

0DataRank · unranked

2 citations

Nan Zhang, Jiaqiang Ren, R.P. Somerville, Anh Dinh, David F. Stroncek